Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 2
1969 2
1970 4
1971 4
1972 4
1974 3
1975 3
1976 1
1977 2
1978 7
1979 1
1980 2
1981 3
1982 1
1983 2
1985 3
1987 1
1990 2
1991 3
1992 1
1993 5
1994 2
1995 3
1996 2
1997 1
1998 3
1999 2
2000 6
2001 9
2002 4
2003 8
2004 10
2005 9
2006 11
2007 10
2008 12
2009 13
2010 15
2011 18
2012 22
2013 13
2014 26
2015 25
2016 18
2017 19
2018 23
2019 20
2020 20
2021 23
2022 14
2023 19
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

396 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
Diaz-Manera J, Kishnani PS, Kushlaf H, Ladha S, Mozaffar T, Straub V, Toscano A, van der Ploeg AT, Berger KI, Clemens PR, Chien YH, Day JW, Illarioshkin S, Roberts M, Attarian S, Borges JL, Bouhour F, Choi YC, Erdem-Ozdamar S, Goker-Alpan O, Kostera-Pruszczyk A, Haack KA, Hug C, Huynh-Ba O, Johnson J, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Diaz-Manera J, et al. Among authors: choi yc. Lancet Neurol. 2021 Dec;20(12):1012-1026. doi: 10.1016/S1474-4422(21)00241-6. Lancet Neurol. 2021. PMID: 34800399 Clinical Trial.
Efficacy and Safety of Avalglucosidase Alfa in Patients With Late-Onset Pompe Disease After 97 Weeks: A Phase 3 Randomized Clinical Trial.
Kishnani PS, Diaz-Manera J, Toscano A, Clemens PR, Ladha S, Berger KI, Kushlaf H, Straub V, Carvalho G, Mozaffar T, Roberts M, Attarian S, Chien YH, Choi YC, Day JW, Erdem-Ozdamar S, Illarioshkin S, Goker-Alpan O, Kostera-Pruszczyk A, van der Ploeg AT, An Haack K, Huynh-Ba O, Tammireddy S, Thibault N, Zhou T, Dimachkie MM, Schoser B; COMET Investigator Group. Kishnani PS, et al. Among authors: choi yc. JAMA Neurol. 2023 Jun 1;80(6):558-567. doi: 10.1001/jamaneurol.2023.0552. JAMA Neurol. 2023. PMID: 37036722 Free PMC article. Clinical Trial.
Clinical and Radiological Features of Korean Patients With Anti-HMGCR Myopathy.
Oh EK, Lee SA, Lee HJ, Cha YJ, Kim S, Lee HS, Suh BC, Shin HY, Kim SW, Yoon BA, Oh SI, Kim YH, Cho JY, Cho JH, Kwon KH, Choi YC, Park HJ. Oh EK, et al. Among authors: choi yc. J Clin Neurol. 2023 Sep;19(5):460-468. doi: 10.3988/jcn.2022.0374. Epub 2023 Mar 13. J Clin Neurol. 2023. PMID: 36929062 Free PMC article.
Multifunctional Self-Doped Nanocrystal Thin-Film Transistor Sensors.
Choi D, Park M, Jeong J, Shin HB, Choi YC, Jeong KS. Choi D, et al. Among authors: choi yc. ACS Appl Mater Interfaces. 2019 Feb 20;11(7):7242-7249. doi: 10.1021/acsami.8b16083. Epub 2019 Feb 11. ACS Appl Mater Interfaces. 2019. PMID: 30688430
Nogo-A regulates myogenesis via interacting with Filamin-C.
Park S, Park JH, Kang UB, Choi SK, Elfadl A, Ullah HMA, Chung MJ, Son JY, Yun HH, Park JM, Yim JH, Jung SJ, Kim SH, Choi YC, Kim DS, Shin JH, Park JS, Hur K, Lee SH, Lee EJ, Hwang D, Jeong KS. Park S, et al. Among authors: choi yc. Cell Death Discov. 2021 Jan 6;7(1):1. doi: 10.1038/s41420-020-00384-x. Cell Death Discov. 2021. PMID: 33414425 Free PMC article.
396 results